You are currently viewing Oramed Pharma’s CEO Issues Letter to Shareholders

Jan 19, 2017

Dear Shareholders,

All the hard work and dedication in 2017 has successfully positioned Oramed to initiate a U.S. based multicenter 90-day treatment study under a FDA IND focused on the lowering of HbA1c in type 2 diabetic patients later this quarter. This is just one of many milestones achieved in 2017 and one of the forward-looking milestones we anticipate in the coming year.

….. for more

Source: PRNewswire